A carregar...
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
BACKGROUND: The aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer. METHODS: This study established a partition survival model for thr...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7747765/ https://ncbi.nlm.nih.gov/pubmed/33344252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.602185 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|